CMS Switzerland has advised WSP Global on its acquisition of the Lausanne-based BG Bonnard & Gardel Holding, one of Switzerland’s leading engineering consulting firms, following the unanimous approval of BG’s shareholders. BG Consulting
Only one year after the companthiy’s incorporation, Kellerhals Carrard has advised ETH Zurich spin-off EthonAI in its USD 6.8 million oversubscribed seed round. The round was co-led by Earlybird Venture Capital and La Famiglia with
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
Baker McKenzie advised PSP Swiss Property on the conversion of its CHF 1.8 billion bond portfolio to green bonds based on the company’s Green Bond Framework. The Green Bond Framework is tied to a green
Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to USD 380 million, including an upfront payment of USD 270 million. With this acquisition of Maryland’
The Swiss Federal Supreme Court decided on the dispute about “Commune de Champagne PDO” in two judgements (December 23, 2022, 2C_407/2021; March 22, 2022, 2C_381/2021). The Canton de Vaud had introduced, in January 2021, a PDO “Commune de Champagne” for
Credit Suisse, acting through its London branch, successfully completed its issuance of EUR 750 m aggregate principal amount of 5.550 per cent. senior notes due 2026. Credit Suisse issued the Notes through its London branch in two separate
Kellerhals Carrard Zurich has expanded its Executive Board from three to four persons. This is both in recognition of the firm’s major growth in recent years and to initiate a generation shift. Cornelia Stengel (
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. Through this
The controlling shareholder of Reuge, the renowned music box producer, successfully completed the sale of a majority stake in the Reuge manufacture to the Swiss luxury watchmaker De Bethune. The independent watchmaker, known for its
